Dexilant is a delayed-release capsule containing dexlansoprazole for adults with gastro-oesophageal reflux disease, frequent heartburn, or erosive oesophagitis. Its dual timed-release design lowers stomach acid and supports control of acid-related oesophageal symptoms.
Dexilant is a delayed-release capsule containing dexlansoprazole, a proton pump inhibitor used for acid-related oesophageal symptoms. It is prescribed for adults with gastro-oesophageal reflux disease, frequent heartburn, and erosive oesophagitis. Dexlansoprazole lowers stomach acid production through two timed releases within the digestive tract.
Dexilant contains dexlansoprazole, a proton pump inhibitor, often shortened to PPI. PPIs reduce acid made by specialised stomach cells by blocking the proton pump, an enzyme involved in the final stage of acid secretion. This can relieve burning behind the breastbone and give irritated oesophageal tissue time to heal. [1]
GERD means gastro-oesophageal reflux disease. It occurs when stomach contents repeatedly move upwards into the oesophagus, causing heartburn, sour-tasting reflux, regurgitation, chest discomfort, cough, or disturbed sleep.
Dexilant is used in acid-related conditions that include:
A useful practical detail is that reflux pain can mimic chest pain. Sudden chest pressure, breathlessness, sweating, pain spreading to the arm or jaw, or collapse needs urgent medical assessment rather than extra acid-reducing capsules.
Dexilant is a delayed-release capsule containing dexlansoprazole, a proton pump inhibitor used for acid-related oesophageal symptoms. Dexlansoprazole lowers stomach acid production through two timed releases within the digestive tract.
PPIs reduce acid made by specialised stomach cells by blocking the proton pump, an enzyme involved in the final stage of acid secretion. [1]
Dexilant capsules use dual delayed-release technology. The capsule contains granules designed to release dexlansoprazole in two separate phases as they move through the digestive tract. The first release begins earlier, while the second release extends acid suppression later in the day.
The European Medicines Agency describes PPIs as medicines that suppress gastric acid by inhibiting the stomach proton pump. [2]
Dexilant is used in acid-related conditions that include:
Dexilant, lansoprazole, pantoprazole, omeprazole, rabeprazole, and esomeprazole belong to the PPI family. They share the same broad target: the stomach’s acid-producing proton pump. The main difference with Dexilant is its two-stage delayed release.
| Approach | Acid-control pattern | Typical clinical role |
|---|---|---|
| Dexilant with dexlansoprazole | Dual delayed release | GERD symptoms and erosive oesophagitis where extended coverage is desired |
| Standard PPI such as lansoprazole or pantoprazole | Single main delayed release | Regular acid suppression, often timed around meals |
| H2-receptor blocker | Shorter acid reduction through histamine blockade | Intermittent or night-time symptoms in selected patients |
NICE guidance for adults with dyspepsia and GERD supports PPIs as a core treatment option, with medicine choice based on symptoms, response, co-existing conditions, and the intended treatment duration. [5]
A stronger dose is not automatically the better choice. Someone with meal-related symptoms may respond well to a conventional PPI, while someone with symptoms extending into the evening may benefit from Dexilant’s release profile. Persistent symptoms despite regular treatment should prompt a review of diagnosis, adherence, diet, and alarm symptoms.
Dexilant is contraindicated in people with a serious allergic reaction to dexlansoprazole, lansoprazole, or another ingredient in the capsule. Concomitant use of a medicine containing rilpivirine is contraindicated because acid suppression can reduce rilpivirine absorption and compromise antiviral treatment.
Extra care is needed with medicines whose absorption depends on stomach acidity. These include certain antifungal treatments, iron preparations, and some HIV medicines. Dexlansoprazole may also affect treatment plans involving warfarin, tacrolimus, methotrexate, digoxin, or medicines that lower magnesium.
The FDA prescribing information advises caution when dexlansoprazole is combined with medicines affected by gastric pH or with drugs that may require monitoring during PPI therapy. [4]
Dexilant is NOT for you if you have had a serious allergic reaction to dexlansoprazole, lansoprazole, or another ingredient in the capsule. Avoid it if you use a medicine containing rilpivirine, since acid suppression can reduce rilpivirine absorption and compromise antiviral treatment.
Most people tolerate Dexilant without serious problems. Headache, diarrhoea, abdominal discomfort, nausea, wind, vomiting, and upper respiratory symptoms have been reported with dexlansoprazole and other PPIs. These effects are often mild, yet persistent diarrhoea or abdominal pain deserves attention.
Long-term PPI treatment can affect magnesium levels, vitamin B12 absorption, and bone health in people with risk factors or prolonged exposure. The MHRA has warned that long-term PPI use may be associated with an increased fracture risk, mainly in people using high doses or taking treatment for extended periods. [3]
Seek urgent medical help for severe symptoms such as:
A subtle issue patients often miss is that heartburn can improve while another problem continues. Difficulty swallowing, painful swallowing, vomiting blood, black stools, unexplained weight loss, or persistent vomiting require prompt clinical review.
Dexilant works best when it is taken consistently, not only after a heavy meal or severe burning episode.
Common errors include:
Some people stop a PPI and experience a temporary rebound increase in acid symptoms. This does not prove the medicine caused permanent dependency. It can reflect rebound acid secretion after regular suppression, which is why gradual changes may be preferred for some long-term users.
In clinical practice, prescribers often look beyond the word heartburn. They ask whether symptoms occur after meals, overnight, during exercise, or with swallowing, because these patterns can point to different causes.
Doctors commonly expect early symptom improvement before complete healing of erosive oesophagitis. They also review ongoing PPI treatment rather than leaving it unchanged indefinitely. The WHO Model List of Essential Medicines includes omeprazole as a representative PPI, reflecting the established role of this medicine class in acid-related disease management.
A clinician may reassess treatment when a person needs prolonged therapy, develops breakthrough symptoms, or has risk factors for low magnesium, fractures, or nutrient deficiency. The aim is the lowest regimen that controls the diagnosed condition.
Dexilant starts reducing acid after treatment begins, yet symptom relief varies with the degree of inflammation and the pattern of reflux. Burning may improve within days, while erosive oesophagitis may need a longer prescribed course to heal. The FDA prescribing information revised in 2023 distinguishes symptom treatment from healing and maintenance therapy. Persistent symptoms despite regular use need review rather than repeated self-adjustment. A clinical review can also assess whether another diagnosis explains ongoing symptoms.
Dexilant capsules may be taken with or without food because of their dual delayed-release design. This gives more flexibility than some PPIs that are routinely timed before meals. A consistent daily routine still matters. The EMA’s 2010 GERD guideline recognises acid suppression as a central pharmacological approach for reflux disease.
Daily treatment is used when it has been prescribed for GERD or erosive oesophagitis. Duration depends on the diagnosed condition, response, and individual risk factors such as fracture history, low magnesium, or interacting medicines. The MHRA highlighted long-term PPI considerations in its 2012 drug-safety communication on fracture risk. Regular review is most relevant when therapy continues beyond the initial treatment period.
Take the missed capsule when remembered unless the next scheduled dose is near. Skip the forgotten dose if it is nearly time for the next one, then resume the usual schedule. Do not double the next dose. This approach is consistent with the FDA’s 2023 prescribing guidance for delayed-release dexlansoprazole capsules.
Acute interstitial nephritis is an uncommon but serious inflammatory kidney reaction reported with PPIs. Possible signs include reduced urine, blood in urine, fever, rash, fatigue, or swelling, though symptoms can be non-specific. The WHO included pharmacovigilance principles in its 2023 medicines safety framework, emphasising assessment of suspected medicine-related reactions. New urinary symptoms or marked swelling during treatment need prompt medical assessment.
Some people develop rebound acid symptoms after stopping regular PPI therapy, especially after prolonged use. A clinician may recommend a step-down plan, intermittent treatment, or a different approach depending on the original diagnosis. NICE guidance updated in 2014 supports reviewing ongoing acid suppression and tailoring treatment to symptom control. Do not stop suddenly if Dexilant was prescribed to heal erosive oesophagitis without discussing the treatment plan.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
